DuChemBIO Co.,Ltd. (KOSDAQ:176750)

DuChemBIO Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Operating Revenue	35,601	34,695
Other Revenue	-	-0
Revenue	35,601	34,695
Revenue Growth (YoY)	2.61%	-
Cost of Revenue	23,367	22,898
Gross Profit	12,234	11,797
Selling, General & Admin	5,548	5,087
Research & Development	-	205.31
Operating Expenses	7,158	6,541
Operating Income	5,076	5,256
Interest Expense	-1,091	-1,364
Interest & Investment Income	89.64	90.89
Earnings From Equity Investments	1,106	-69.64
Currency Exchange Gain (Loss)	-34.84	-7.99
Other Non Operating Income (Expenses)	30.23	68.38
EBT Excluding Unusual Items	5,177	3,974
Gain (Loss) on Sale of Investments	387.82	92.13
Gain (Loss) on Sale of Assets	-0.18	16.28
Asset Writedown	-	-30.7
Pretax Income	5,564	4,052
Income Tax Expense	-2,429	51.23
Net Income	7,994	4,001
Net Income to Common	7,994	4,001
Net Income Growth	99.82%	-
Shares Outstanding (Basic)	27	27
Shares Outstanding (Diluted)	27	27
Shares Change (YoY)	0.58%	-
EPS (Basic)	298.00	150.00
EPS (Diluted)	298.00	150.00
EPS Growth	98.67%	-
Free Cash Flow	5,440	7,293
Free Cash Flow Per Share	202.79	273.46
Gross Margin	34.36%	34.00%
Operating Margin	14.26%	15.15%
Profit Margin	22.45%	11.53%
Free Cash Flow Margin	15.28%	21.02%
EBITDA	10,641	11,016
EBITDA Margin	29.89%	31.75%
D&A For EBITDA	5,565	5,760
EBIT	5,076	5,256
EBIT Margin	14.26%	15.15%
Effective Tax Rate	-	1.26%
Advertising Expenses	76.18	62.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.